Similarly, there have been no differences in the survival outcomes reported for breast cancer with or without germline BRCA1/2 pathogenic variants in young women, except for a trend towards improved survival for carriers of BRCA1/2 mutations with TNBC compared with non-carriers [122]. The gene discussed is BRCA1; the disease is breast cancer.